Stryker Co. (NYSE:SYK) Shares Sold by Smart Portfolios LLC

Smart Portfolios LLC trimmed its stake in shares of Stryker Co. (NYSE:SYK) by 1.6% during the 4th quarter, HoldingsChannel.com reports. The firm owned 2,511 shares of the medical technology company’s stock after selling 42 shares during the quarter. Smart Portfolios LLC’s holdings in Stryker were worth $904,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of SYK. EverSource Wealth Advisors LLC grew its holdings in Stryker by 19.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,469 shares of the medical technology company’s stock worth $529,000 after acquiring an additional 243 shares in the last quarter. Sequoia Financial Advisors LLC increased its stake in Stryker by 7.5% in the 4th quarter. Sequoia Financial Advisors LLC now owns 12,074 shares of the medical technology company’s stock valued at $4,347,000 after buying an additional 838 shares during the period. HighTower Advisors LLC increased its stake in Stryker by 3.0% in the 4th quarter. HighTower Advisors LLC now owns 432,332 shares of the medical technology company’s stock valued at $155,661,000 after buying an additional 12,479 shares during the period. Moors & Cabot Inc. grew its stake in shares of Stryker by 0.4% during the 4th quarter. Moors & Cabot Inc. now owns 10,686 shares of the medical technology company’s stock worth $3,847,000 after purchasing an additional 43 shares during the period. Finally, Natural Investments LLC acquired a new position in shares of Stryker during the 4th quarter worth $1,528,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the transaction, the director now owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Analyst Upgrades and Downgrades

SYK has been the topic of a number of research analyst reports. Argus set a $450.00 target price on Stryker in a report on Monday, February 3rd. Royal Bank of Canada boosted their target price on Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 29th. Stifel Nicolaus boosted their target price on Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a research note on Wednesday, January 29th. Morgan Stanley raised Stryker from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $370.00 to $445.00 in a report on Monday, December 2nd. Finally, The Goldman Sachs Group set a $422.00 price target on Stryker in a research report on Tuesday, March 4th. Five research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $421.90.

Stryker Trading Down 1.3 %

Stryker stock opened at $365.35 on Wednesday. The company has a market capitalization of $139.41 billion, a price-to-earnings ratio of 47.08, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19. The stock has a 50-day moving average price of $382.70 and a 200 day moving average price of $373.40. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the previous year, the firm earned $3.46 earnings per share. Sell-side analysts anticipate that Stryker Co. will post 13.47 EPS for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.92%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s payout ratio is currently 43.30%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.